Search clinical trials for: BIA 9-1067 5 mg

Total 1797 results

Bial - Portela C S.A.

Completed

Study of BIA 9-1067 to Investigate Its Effect on Levodopa Pharmacokinetic

Parkinson Disease

Portugal
Galderma R&D

Completed

Photodynamic Therapy (PDT) With Metvix Cream 160 mg/g Versus PDT With Placebo Cream in Patients With Primary Nodular Basal Cell Carcinoma

Basal Cell Carcinoma

United States
Bial - Portela C S.A.

Completed

Bioavailability and Bioequivalence Between Two Active Pharmaceutical Ingredient (API) Sources of Opicapone (OPC)

Parkinson Disease

United Kingdom
Bial - Portela C S.A.

Completed

Single-dose Pharmacokinetics and Relative Bioavailability of Two Different Formulations of Opicapone

Parkinson Disease
Bial - Portela C S.A.

Completed

Relative Bioavailability and Bioequivalence Of Different Formulations of Opicapone in Healthy Volunteers

Parkinson
Bial - Portela C S.A.

Completed

Effect of Three Multiple-dose Regimens of BIA 9 1067 at Steady-state on the Levodopa Pharmacokinetics

Parkinson's Disease (PD)

France
Galderma R&D

Completed

Phase 3b Study of Metvix NDL-PDT Versus Metvix c-PDT in Subjects With Actinic Keratoses (COMET2)

Actinic Keratoses

Spain, France, Germany, Netherlands, Sweden
Bial - Portela C S.A.

Completed

Absorption, Distribution, Metabolism and Excretion of [14C] Labelled BIA 5-1058

Cardiovascular Diseases

United Kingdom
Bial - Portela C S.A.

Recruiting

OpiCapone Effect on Motor Fluctuations and pAiN (OCEAN)

Parkinson Disease

United Kingdom
Pfizer

Terminated

An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of Schizophrenia

Schizophrenia

United States
Suzhou Kintor Pharmaceutical Inc,
Suzhou Koshine Biomedica, Inc.

Active, not recruiting

Phase III Study of KX-826 With Adult Male Patients With AGA

Androgenetic Alopecia

China
Bial - Portela C S.A.

Completed

Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]-BIA 9-1067

Parkinson Disease

United Kingdom
Bial - Portela C S.A.

Completed

Pharmacokinetics of BIA 9-1067 in Healthy Japanese and Caucasian Subjects

Parkinson Disease

United States
Bial - Portela C S.A.

Completed

Absorption, Distribution, Metabolism and Excretion of [14C]-Labeled BIA 9-1067 and Metabolites

Parkinson Disease

Switzerland
Bial - Portela C S.A.

Completed

Pharmacokinetics of BIA 9-1067 in Subjects With Hepatic Impairment

Parkinson's Disease

France, Russian Federation
Bial - Portela C S.A.

Completed

An Open-label Study in Healthy Male Subjects to Assess the Absorption, Distribution, Metabolism and Excretion of [14C]-Labelled BIA 9-1067 and Metabolites

Parkinson's Disease (PD)

Netherlands
Suzhou Kintor Pharmaceutical Inc,

Completed

Phase II Study Evaluating the Efficacy and Safety of KX-826

Androgenetic Alopecia (AGA)

China
Bial - Portela C S.A.

Completed

Dosage Form Proportionality of Opicapone To-Be-Marketed Formulation

Epilepsy
Institute of Hematology & Blood Diseases Hospital

Not yet recruiting

Ruxolitinib as GVHD Prophylaxis in AA Patients

The Prophylactic Value of Ruxolitinib for aGVHD in HSCT Recipients of AA
Bial - Portela C S.A.

Completed

Relative Bioavailability and Bioequivalence of Opicapone

Parkinson Disease

United Kingdom
Bial - Portela C S.A.

Active, not recruiting

OpicApone Sleep dISorder (OASIS)

Parkinson Disease

Portugal
Bial - Portela C S.A.

Completed

A Single Oral Ascending Dose Study of BIA 9-1067 in Healthy Male Subjects

Parkinson Disease

France
Bial - Portela C S.A.

Completed

Bioavailability and Bioequivalence Study of Two Different Sources of Opicapone

Parkinson Disease

Germany
Bial - Portela C S.A.

Completed

Effect of Food on Opicapone

Parkinson Disease
Bial - Portela C S.A.

Completed

Pharmacokinetics of BIA 9-1067 and Its Metabolites in Healthy Male Elderly Subjects and in Healthy Male Young Subjects

Parkinson Disease

France
Bial - Portela C S.A.

Completed

Comparative Bioavailability Study of BIA 9-1067 25 mg Capsules

Parkinson

Canada
Bial - Portela C S.A.

Completed

Absorption, Distribution, Metabolism and Excretion of [14C]- Labeled BIA 5-453 and Metabolites

Hypertension | Congestive Heart Failure

Switzerland
Linnaeus University
Karolinska Institutet; Region Östergötland; Kronoberg County Council; Landstinget...

Recruiting

Evaluation of the Efficiacy of Mecobalamine in the Treatment of Long-term Pain in Women Diagnosed With Fibromyalgia

Fibromyalgia

Sweden
Bial R&D Investments, S.A.

Recruiting

Efficacy, Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BIA 28-6156 in GBA-PD (ACTIVATE)

Parkinson's Disease

United States, Spain, France, Italy, Netherlands, Germany, United Kingdom, Canada, Poland, Portugal, Sweden
Bial - Portela C S.A.

Completed

Tolerability, Pharmacokinetics and Pharmacodynamics of BIA 9-1067

Parkinson's Disease (PD)

France
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Completed

First in Human Study of M4344 in Participants With Advanced Solid Tumors

Solid Tumor | Advanced Solid Tumor

Spain, United States, Netherlands, United Kingdom
Bial - Portela C S.A.

Completed

Pharmacokinetics of BIA 5-453 and Its Metabolites

Hypertension | Chronic Heart Failure

France
Bial - Portela C S.A.

Completed

Bioavailability Study of BIA 5-453

Hypertension | Congestive Heart Failure

France
Bial - Portela C S.A.

Completed

Effect of BIA 9-1067 on the Pharmacokinetics and Pharmacodynamics of Warfarin

Parkinson's Disease (PD)

Portugal
Bial - Portela C S.A.

Completed

Effect of Opicapone at Steady State on Warfarin Pharmacokinetics

Parkinson's Disease
Quark Pharmaceuticals

Terminated

Phase 2/3, Randomized, Double-Masked, Sham-Controlled Trial of QPI-1007 in Subjects With Acute Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)

Non Arteritic Anterior Ischemic Optic Neuropathy

United States, Australia, Germany, China, India, Italy, Singapore, Israel
Bial - Portela C S.A.

Completed

Tolerability, Pharmacokinetics and Pharmacodynamics of Six Multiple Rising Dose Regimens of BIA 5-453

Hypertension | Chronic Heart Failure
AstraZeneca

Active, not recruiting

A Study of CIN-107 in Adults With Primary Aldosteronism

Primary Aldosteronism | Hyperaldosteronism

United States
Bial - Portela C S.A.

Completed

Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Dose Regimens of BIA 5-453

Hypertension

France
Bial - Portela C S.A.

Completed

Absorption, Distribution, Metabolism and Excretion of [14C]-Labelled BIA 3-202 and Metabolites

Parkinson's Disease

Switzerland
Pfizer

Completed

A Study Of CP-690,550 In Stable Kidney Transplant Patients

Kidney Transplant

United States
Bial - Portela C S.A.

Completed

Effect of BIA 9-1067 on the Pharmacokinetics of Repaglinide

Parkinson Disease

Portugal
Bial - Portela C S.A.

Completed

Absorption, Distribution, Metabolism and Excretion of BIA 5-1058 (ADME)

Pulmonary Arterial Hypertension

Netherlands
University of Virginia

Unknown

IRB-HSR# 14299: The Use of the Intrathoracic Pressure Regulator (ITPR) to Improve Cerebral Perfusion Pressure in Patients With Altered Intracranial Elastance

Traumatic Brain Injury

United States
Bial - Portela C S.A.

Active, not recruiting

eArly levoDopa With Opicapone in Parkinson's paTients wIth motOr fluctuatioNs. (ADOPTION)

Parkinson Disease

Spain, Italy, Portugal, Germany, United Kingdom
Hamamatsu University

Completed

Comparison of Vonoprazan-based Dual and Triple Therapies for H. Pylori Eradication

Gastritis Associated With Helicobacter Pylori

Japan
Bial - Portela C S.A.

Completed

Pharmacokinetic Interaction Between BIA 9-1067 and Standard-release Levodopa/Carbidopa

Parkinson Disease

Canada
Bial - Portela C S.A.

Completed

Effect of Rasagiline on BIA 9-1067 Pharmacokinetics

Parkinson Disease

France
Bial - Portela C S.A.

Completed

Effect of BIA 9-1067 on Rasagiline Pharmacokinetics

Parkinson Disease

France
JW Pharmaceutical

Recruiting

A Therapeutic Confirmatory Study of Epaminurad Versus Febuxostat in Gout Patients (EPIC)

Gout

Korea, Republic of

3

Subscribe